Navigation Links
FDA Approves New Combination Product Oral Contraceptive
Date:5/6/2010

SILVER SPRING, Md., May 6 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Natazia, a combination hormonal tablet for use as an oral contraceptive.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Natazia contains two female hormones, an estrogen (estradiol valerate) and a progestin (dienogest), and is the first four-phasic oral contraceptive marketed in the United States. Four-phasic refers to the doses of progestin and estrogen varying at four times throughout each 28-day treatment cycle.

"Nearly 12 million women in the United States and more than 100 million women worldwide currently use oral contraceptives," said Scott Monroe, M.D., director of FDA's Division of Reproductive and Urologic Products. "The approval of Natazia provides another option for women who choose to use an oral contraceptive as their method of contraception."

The safety and efficacy of Natazia as an oral contraceptive was evaluated in two multicenter phase 3 clinical trials in North America and Europe. The trials involved 1,867 women and nearly 30,000 28-day treatment cycles.  Natazia was found to be effective as a hormonal contraceptive in both studies.  

The most common side effects observed with Natazia include irregular bleeding, breast tenderness, headaches, nausea and vomiting, increased weight, and acne.  Women older than 35 who smoke should not use this product. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use.  

Natazia is manufactured by Bayer HealthCare Pharmaceuticals of Wayne, N.J.

Media Inquiries: Elaine Gansz Bobo, 301.796.7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
2. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
3. FDA Approves New Device for Adults with Severe and Persistent Asthma
4. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
5. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
6. FDA Approves First Totally Implanted Hearing System
7. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
8. FDA Approves Name Change for Heartburn Drug Kapidex
9. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
10. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
11. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
(Date:5/3/2016)... watching a film or TV show in high definition, you may not be familiar with ...  is a renowned authorized reseller of the medical industry,s top brands as well as a ... ... ... Although initially introduced ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... Washington, DC (PRWEB) , ... May 06, 2016 ... ... Blum, Executive Vice President at CareFirst Blue Cross BlueShield and Former Principal Deputy ... Officer at CareMore - an Anthem Company; Steve Ondra, MD, Chief Medical Officer ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is ... (RWS) for public stakeholder review. The stakeholder review is an important opportunity for interested ... goals and delivers value to the wool industry., The RWS is intended to be ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May 8, ... terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured veterans ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... advisory organization, announces McLaughlin & Smoak Benefits as the latest addition to its ... Benefits has a dedicated team of compliance, wellness, human resources, and health care ...
Breaking Medicine News(10 mins):